CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 6. Mature wild-type Hck and Hck499F have different requirements for on-going support by Hsp90. A, 293T cells expressing wild-type Hck or Hck499F were treated 48 h posttransfection with 100 µg/ml cycloheximide for 2 h and then with either DMSO (-) or 2.5 µM GA (+) for 60 min. The cells were lysed and the whole cell lysates Western blotted with anti-phosphotyrosine ({alpha}-pY) and anti-Hck antibodies. The positions of molecular mass markers (in kDa) are shown on the Xright. B, Hck499F was immunoprecipitated from aliquots of the whole cell lysates shown in A and subjected to an in vitro autophosphorylation reaction or Western blotting with an anti-Hck antibody. C, 293T cells expressing either wild-type Hck or Hck499F were treated 48 h posttransfection with 100 µg/ml cycloheximide for 2 h and then with either DMSO (-) or 2.5 µM GA (+) for 60 min. Wild-type Hck and Hck499F were immunoprecipitated from lysates of the cells and Western blotted with anti-Hsp90, anti-p50Cdc37, and anti-Hck antibodies.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation